Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy

Pharmacogenomics Journal

Volumn 15, Issue 5, 2015, Pages 397-404

  Pare Brunet L ^a,b,c   Sebio, A ^a   Salazar, J ^a,d   Berenguer Llergo, A ^b   Rio E ^a,d   Barnadas, A ^a   Baiget, M ^a,d   Paez D ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; B RAF KINASE; FLUOROURACIL; METASTIN; OXALIPLATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; KISS1 PROTEIN, HUMAN; KISSPEPTIN; PLATINUM COMPLEX; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; FEMALE; GENE INTERACTION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; ITGAV GENE; KISS1 GENE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; VEGFR2 GENE; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETIC ASSOCIATION STUDY; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENETIC ASSOCIATION STUDIES; HUMANS; KISSPEPTINS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84942197262     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.1     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
4. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
5. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
6. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
7. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
8. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
9. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
10. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
11. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
12. Cho SG, Yi Z, Pang X, Yi T, Wang Y, Luo J, et al. Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res 2009; 69: 7062-7070.
13. Beck BH, Welch DR. The KISS1 metastasis suppressor: a good night kiss for disseminated cancer cells. Eur J Cancer 2010; 46: 1283-1289.
14. Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
15. Pare-Brunet L, Glubb D, Evans P, Berenguer-Llergo A, Etheridge AS, Skol AD, et al. Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway. Hum Mutat 2014; 35: 227-235.
16. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, et al. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2011; 17: 5783-5792.
17. Sebio A, Pare L, Paez D, Salazar J, Gonzalez A, Sala N, et al. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genom 2013; 23: 142-147.
18. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 2011; 17: 5257-5267.
19. Dong G, Guo X, Fu X, Wan S, Zhou F, Myers RE, et al. Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer. Cancer Sci 2012; 103: 561-568.
20. Smith AV. Manipulating HapMap Data Using HaploView. CSH Protoc 2008; 2008: 63-71.
21. Owzar K, Li Z, Cox N, Jung S-H. Power and sample size calculations for SNP association studies with censored time-to-event outcomes. Genet Epidemiol 2012; 36: 538-548.
22. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr AC-19 1974; 19: 716-723.
23. Dudbridge F, Gusnanto A, Koeleman BP. Detecting multiple associations in genome-wide studies. Hum Genom 2006; 2: 310-317.
24. Benjamini YaH Y. Controlling the false discovery rate: a practical and powerful approach to multipletesting. J R Statist Soc Ser B 1995; 57: 289-300.
25. Benjamini YaY D. The control of the false discovery rate in multiple hypothesis testing under dependency. Ann Stat 2001; 29: 1165-1188.
26. Hothorn TKHK, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat 2006; 15: 651-674.
27. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 2011; 11: 247.
28. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, et al. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One 2013; 8: e66774.
29. Hansen TF, Garm Spindler KL, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenom J 2011; 11: 53-60.
30. Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der Zee AH, et al. Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clin Cancer Res 2012; 18: 4526-4537.
31. KISS1 KiSS-1 metastasis-suppressor [Homo sapiens (human)]. http://www.ncbi. nlm.nih.gov/gene/3814; accessed on April 2014.